On heels of land­mark ap­proval, Bris­tol My­ers Squibb em­barks on bil­lion-dol­lar on­col­o­gy deal with metasta­t­ic can­cer start­up

Af­ter the FDA ap­proved BMS’s new LAG-3 on­col­o­gy drug late last week, Bris­tol My­ers Squibb is div­ing head­first in­to a hy­per-niche field of on­col­o­gy re­search …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER